

Page 6, line 1 change "increse" to read --increase--

Page 6, line 10 after "example" inert --,--

Page 7, line 18, Section B change "(Anhydriys)" to read --
(Anhydrous)

Page 8, line 16 change "This" to read --The--

Page 8, line 17 after "examples" insert --was--

Page 10, line 8 after "was prepared" insert the following:

a

---Benzyl Alcohol NF	1.50ml
Sodium Chloride USP	0.82g
Methyl Cellulose (4000 cps.)	1.33g
Acetic Acid NF	0.10g
Sodium Acetate (Anhydrous)	0.27g
Sorbitol Solution USP	5.00ml
Cyanocobalamin USP	0.10g
Water, Purified USP	q.s. 100.000ml

This composition was tested in three humans as described in the previous example. The nasal administration of 200ug of B₁₂ in 0.2cc gave the following serum B₁₂ levels:---

Page 11, line 13 change "Bengulkonium" to read --
Benzalkonium--

Page 11, line 16 change "intrumural" to read --intranasal--

Page 11, line 25 change "Baseline" to read --baseline--

REMARKS

A number of typographical errors have been corrected. Additionally, a section which appeared in the parent application and was inadvertently omitted at the time of preparing the above identified continuation in part application has been resubmitted. In that connection the examiner is respectfully requested to compare lines 1 through 11 on page 11 of the parent application with the amendment proposed for page 10 line 8 of this application after "prepared".

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D. C. 20231, on 1-12-57

Date: 1-12-57

Henry T. Burke, Reg. No. 18975

Respectfully submitted,

Henry T. Burke, Reg. No: 18975
c/o Wyatt, Gerber et al
261 Madison Avenue
New York, NY 10016
Tel: (212) 687-0911